With the help of medical technology solutions and innovation we want to save as many heart failure patients as possible. About Scandinavian Real Heart AB – Only around 8,000 heart transplants take place annually worldwide and the availability of donated hearts is very limited. The need is great and patients with heart failure die waiting for a new heart. Scandinavian Real Heart AB is developing a heart pump (TAH) that mimics the body's natural circulation and that can be used as a transitional solution for patients waiting for a heart transplant. Successful studies have been carried out on anesthetized animals …

69 similar entities Type: Startup Activities: deeptech healthtech Technologies: Synthetic Biology

Levearging the therapeutic potential of mitochondria cellvie is the leader in Therapeutic Mitochondria Transplantation (TMT). The team is seeking to bring about a novel treatment modality, leveraging the therapeutic potential of mitochondria, the powerhouses of the cell. Therapeutic Mitochondria Transplantation, an approach for mitochondria augmentation and replacement, was developed by Dr. James McCully at Harvard Medical School. cellvie was founded to take this technology from bench to bed, starting in heart attacks and solid organ transplantation. Therapeutic Mitochondria Transfer, Mitochondria, Ischemia-Reperfusion Injury, and Solid Organ Transplantation

60 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Driven by the heart We officially combined with Bristol Myers Squibb to further strengthen our scientific capabilities and treatments for cardiovascular patients. Visit www.bms.com to learn more about our work to produce the next generation of medicines for patients with serious cardiovascular disease. For more information on the acquisition, see our press release at: https://one.bms.com/40FsT7W Genetic Heart Disease, Cardiomyopathy, biotechnology, cardiovascular disease, heart failure, precision medicine, therapeutics, drug discovery, drug development, and R&D

Type: Startup Activities: healthtech biotech deeptech Technologies: Synthetic Biology

Nuuron is developing a Digital Drug to treat Alzheimer’s Disease. Nuuron is a VC backed, clinical stage neurotech company that develops the Memory-Pacemaker, a non-invasive, photonic neurostimulation to re-enable patients with Alzheimer's Disease to store and recall memories again.

57 similar entities Type: Startup Activities: it services Technologies: Synthetic Biology

Secretome is a clinical-stage company focused on orphan and underserved cardiac diseases Secretome Therapeutics is a clinical-stage cell therapy company focused on orphan and underserved cardiac diseases. STM-01, the lead drug, is a neonatal cardiac progenitor cell (nCPC) isolated from cardiac tissue excised during life-saving, open-heart surgery on newborns with congenital heart defects. The main target indication for STM-01 is Duchenne muscular dystrophy-associated cardiomyopathy (DMD-CM).

63 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

less complexity. more biology. At Chromodynamics, we are on a mission to deliver instruments that eliminate guesswork from drug development and prescription. Our unique technology allows for an enormous improvement in speed, efficacy, and cost with which exciting new treatments like immunotherapy are developed. We have been recognised as one of the most promising startups in the Eindhoven Brainport region and are expanding our team to ramp up our product development. Imaging systems, Multispectral imaging, Real-time analysis, Chemical imaging, Spectroscopy, Scientific instruments, Contract research, and Data analysis

931 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

CorWave develops and manufactures innovative implantable blood pumps based on a breakthrough membrane technology. CorWave is a French company developing innovative cardiac assist devices. CorWave’s wave membrane pump is a breakthrough technology that differs from today’s commercially available left ventricular assist devices (LVADs) by its physiological operation, designed to mimic a pulse and blood flow rates similar to those of a healthy heart. Ultimately, CorWave’s membrane pump technology is expected to reduce the complications associated with current devices and improve the management of heart failure patients. A member of the French Tech 120, CorWave was founded in 2012 by start-up …

59 similar entities Tags: FrenchTech120 Type: Startup Activities: deeptech healthtech manufacturing nanotech Technologies: Synthetic Biology

Health Research & Development Center BIONOVEO offers project leaders, whether they are industrial or academic, the skills and biological, technical and methodological resources necessary for the development of new therapeutic and diagnostic strategies, as well as their production processes.

169 similar entities Type: SMB Activities: deeptech Technologies: Synthetic Biology

A Healthier Life With Every Beat FineHeart is a clinical stage medical device company based in Bordeaux, France. Its innovative product, FLOWMAKER®, has the potential to treat 200,000 patients with advanced heart failure each year. FineHeart will initially target the 50,000 most severe patients who are eligible for cardiac assistance. Initial estimates value this market segment to be worth over US$5 billion. FineHeart was founded by CEO Arnaud Mascarell and a team of internationally renowned cardiac surgeons and electro-physiologists, including Dr. Stephane Garrigue, CSO and inventor of the concept, and Dr. Philippe Ritter, co-inventor of cardiac resynchronization therapy (CRT). The …

87 similar entities Type: Startup Activities: deeptech healthtech manufacturing Technologies: Synthetic Biology

Galvani Bioelectronics is a joint venture between GSK and Verily Life Sciences. We are devoted to the development of life changing neuromodulation therapies for patients with chronic disease. Medical Devices

103 similar entities Type: SMB Activities: deeptech healthtech Technologies: Synthetic Biology

HVR Cardio is a medical device company focused on developing first-generation transcatheter mitral valve repair solutions. Our minimally invasive technology has the potential to enable safer, faster, and less traumatic cardiac interventions for mitral regurgitation patients worldwide. HVR Cardio’s innovative HELIX ring technology has been carefully designed to fit the anatomy of the mitral valve. This allows fast and easy implantation and most importantly, restoration of the valve geometry leading to uncompromised clinical efficacy. With our catheter-based product, we expect to reduce the invasiveness, operation time, and morbidity associated with mitral valve repair operations. This would allow effective treatment of …

60 similar entities Type: Startup Activities: deeptech healthtech Technologies: Synthetic Biology

Leading the way for leaflet modification Pi-Cardia is a medical device company and market leader in the development of a broad portfolio of leaflet modification solutions for treating heart valves. The company has years of knowledge and expertise accumulated in degenerated valves, including calcification patterns, mode of valve failure, and impact of various methods of leaflet modification. ShortCutTM is designed to provide a safe, simple, and effective way to split leaflets of a pre-existing valve to enable TAVR in patients at risk for coronary obstruction and may assist in preserving coronary access. Medical Device, Aortic Stenosis, Precautions Catheter-System, Cardiovascular, leaflet …

66 similar entities Type: Startup Activities: deeptech biotech healthtech Technologies: Synthetic Biology

Restore your body through the power of self-regeneration Founded in 2020, Healshape is a French global regenerative medicine company, with a clear mission: “Enabling people to restore their physical integrity through self-regeneration”. We are committed to transforming the way soft tissue reconstruction is approached, moving away from synthetic implants and toward biological harmony. Biotechnology, Regenerative medecine, Médecine régénérative, Reconstruction mammaire, Cancer du sein, Breast cancer, Breast regeneration, Breast reconstruction, 3D bioprinting, Tissue engineering, Biologie cellulaire, Impression 3D, Funds raising, Tissue engineered products, Lyon, France, self-regeneration, and Start-up

86 similar entities Type: Startup Activities: deeptech Technologies: 3D Printing Synthetic Biology

Keep track of the heart. Everywhere. All the time. Vectorious Medical Technologies develops novel treatment for heart failure patients which is based on physician directed, patients’ self-management paradigm. Leveraging its advanced, first of its kind, implantable V-LAP platform, which harvests valuable information from the heart’s left atrium, physicians and patients can monitor and manage disease status, prevent hospitalizations and improve quality of life. The V-LAP system is an investigational device which is currently under evaluation in multiple clinical studies in Europe, Israel and the U.S. Medical Devices, Wireless communication, Miniature Implants, Heart Failure, Remote Monitoring, and Sensors

137 similar entities Type: Startup Activities: deeptech healthtech Technologies: Synthetic Biology

Inovative company specialized in the development and manufacture of medical devices EOVE develops and manufactures innovatives products to improve care and quality life with greater freedom for Adult ans Pediatric Patients who suffer from breathing disorders and chronic respiratory diseases.

167 similar entities Type: Startup Activities: healthtech manufacturing deeptech Technologies: Synthetic Biology

Make​ your Own Neuronal Network At MicroBrain Biotech, our mission is to revolutionize drug development by embracing ethical and cruelty-free practices, putting humanity at the center of our work, and relentlessly pursuing groundbreaking discoveries. We are committed to creating innovative solutions that improve the quality of life for patients and their families, while treating all living beings with compassion and respect. Through collaboration, scientific excellence, and a commitment to sustainability, we aim to leave a lasting positive impact on the world of healthcare and beyond.

143 similar entities Type: Startup Activities: deeptech biotech healthtech Technologies: Synthetic Biology

Finding cures for cardiovascular disease through world-class medical research. The Victor Chang Cardiac Research Institute is dedicated to finding cures for cardiovascular disease through world-class medical research. Renowned for the quality of its scientific breakthroughs, the team at the Institute is working urgently to discover better ways of diagnosing, treating and preventing the onset of heart disease. With over 200 scientists and doctors working together across 23 laboratories in NSW and WA, the Victor Chang Cardiac Research Institute has earned its place on the global stage as one of the most respected medical research facilities in the world. The Institute …

57 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Carvolix is a French medical technologies company, commercial and clinical stage, founded by Truffle Capital, that aims to become a global leader in the treatment of structural heart diseases and strokes, world's leading causes of mortality and disability. Carvolix develops novel AI and imaging driven mini-robots that make complex procedures doble by interventional cardiologists, as well as biomimetics heart valves.

65 similar entities Type: Startup Activities: manufacturing deeptech healthtech Technologies: Synthetic Biology

Modulating T-regulatory cells to balance immunity Egle Therapeutics has been founded with a vision to become a game changer in the field of immunomodulating T-regulatory cells (Tregs) through the unique concept of Tregs’ starving while specifically targeting the most immunosuppressive ones.

137 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Gecko Biomedical is a fast-paced medical device company, dedicated to the development of innovative tissue reconstruction solutions. We are leveraging our technology platforms to develop novel solutions to disrupt the field of surgery and positively impact the life of patients.

153 similar entities Type: Startup Activities: healthtech deeptech Technologies: Synthetic Biology

Fighting chronic and fatal diseases Tirecat Health is a company developing a family of novel polymers with amazing potential in the healthcare field. We are propelled with purpose to fight chronic and fatal diseases affecting patients worldwide using our revolutionary technology to improve their quality of life. In order to make this purpose a reality, the company is preparing to move towards the clinical phase to demonstrate the astonishing results seen in preclinical trials.

300 similar entities Type: Startup Activities: healthtech deeptech Technologies: Synthetic Biology

The new way of transplantation Stella Surgical is a European company based in the South of France. It was created to meet the needs of transplant surgeons, procurement and transplant teams, and organ transporters. Our promise: to increase the number of grafts available, and their safety during the entire transplantation process. Thus, we design, develop and market connected and innovative medical devices so that the coordination teams (harvesting and transplant) can plan transplants in the best possible conditions. Patients will therefore be able to benefit from better conditions during their transplant.

65 similar entities Type: SMB Activities: manufacturing deeptech healthtech Technologies: Synthetic Biology

Nasdaq: PAVM PAVmed (NASDAQ: PAVM) is a highly-differentiated, multi-product medical device company employing a unique and proven business model designed to advance products from concept to commercialization much more rapidly and with significantly less capital than the typical medical device company. This model enables us to pursue an expanding pipeline strategy with a view to enhancing and accelerating value creation. cardiology, orthopedics, gastroenterology, and healthcare economics

256 similar entities Type: Startup Activities: deeptech healthtech Technologies: Synthetic Biology

At Orio Therapeutics, our mission is to save lives by making the regenerative medicine dream accessible and a wide-spread reality. We are dedicated to developing novel regenerative drugs with increased efficacy and reduced side-effects, using cutting-edge targeted drug-delivery technologies to create novel therapeutic proteins. Notably, we strive to demonstrate that efficient drug delivery technologies are not confined to the development of complex devices and drug carriers but can be achieved based on clever molecular designs. We aim to initially validate our program pipeline through the development of a therapeutic molecule for myocardial infarction that has the potential to change the …

119 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Pionnier de la thérapie régénératrice cardiaque CellProthera, a biotechnological company, has developed a unique therapeutic technique which enables the structural and functional regeneration of severe post-infarctus cardiac lesions. After European and national (FR/GB) authorization was obtained , CellProthera has started its I/IIB clinical trial in Humans. Heart Regeneration

Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Cell Signaling Technology for Organ Repair and Regeneration Cell Signaling Technology for Organ Repair and Regeneration We care for liver Our advanced therapy aims to restore liver function thanks to immunomodulatory and regenerative properties of Hepastem Cell therapy, Acquired liver diseases, Liver diseases, liver based genetic diseases, NASH, ACLF, Antibodies, Clinical stage, Chronic liver disease, Fatty liver, Acute liver disease, Regenerative medicine, Biotech, and Biotechnology

94 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

RELIEF THERAPEUTICS Holding SA (SIX: RLF; OTCQB: RLFTF, RLFTY) We are a biopharmaceutical company committed to providing therapeutic relief to patients living with rare diseases. Our goal is to advance treatment paradigms and deliver improvements in efficacy, safety and convenience to benefit the lives of patients and their families. Our therapeutic focus is on rare indications for metabolic disorders, pulmonary diseases, and dermatology/connective tissue disorders. Acute Lung Injury, Pulmonary Sarcoidosis, Lung Fibrosis, Acute Respiratory Distress Syndrome, Urea Cycle Disorders, Maple Syrup Urine Disease, Rare Diseases, Epidermolysis Bullosa, Phenylketonuria, PKU, EB, MSUD, UCD, ARDS, Rare Disease, Metabolic Disorders, Acute Lung Disease, …

260 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Unlocking New Targets to Transform the Treatment of Neurodegenerative Diseases Unlocking New Targets to Transform the Treatment of Neurodegenerative Diseases neurodegeneration, RNA therapeutics, physiological upregulation, post-transcriptional upregulation, mRNA, ASO, and SINEUP

209 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

AnaCardio is a privately held clinical stage biopharmaceutical company developing novel drugs to treat heart failure. AnaCardio AB is a privately held clinical stage biopharmaceutical company developing novel drugs to treat heart failure. AnaCardio was founded based on ground-breaking research from Karolinska Institutet showing improved contractility of the heart muscle through a unique and differentiated mechanism. The Company’s lead program AC01, a first-in-class calcium sensitizing inotrope, is an oral ghrelin mimetic small-molecule, which was in-licensed from Helsinn and is now being developed as a contractile agent in heart failure patients. The company has raised over USD 40 million to date. …

57 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Playing music to cells Kolibri revolutionises the way we grow and engineer cells at scale using acoustic waves. 🔍 Book a discovery call: https://calendly.com/tamsin_kolibrilab/discovery-call Showing 10x increase in cell density and 50x reduction in production costs, our patented bioreactors help our partners in drug development unlock patient access to gene therapies, with a proof of principle in AAV gene therapy. Being cell-agnostic and scalable, our process has significant potential across a range of high-value cell-based therapies - or in the cellular agriculture space more broadly. gene therapy, biomanufacturing, cellculture, acoustics, hardtech, and biotech

385 similar entities Type: Startup Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

Innovation. Applied. Founded in 2021, POLYGON Therapeutics is a Paris-based biotechnology company developing precision cardio-immunology therapies targeting inflammatory drivers of cardiovascular disease. The company combines translational human biology, biomarker-driven development and immunology expertise to develop novel therapeutic approaches in cardiovascular disease.

228 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Their life. Your skills. Our technology. CARMAT is a French MedTech that designs, manufactures and markets the Aeson® artificial heart. The Company’s ambition is to make Aeson® the first alternative to a heart transplant, and thus provide a therapeutic solution to people suffering from end-stage biventricular heart failure, who are facing a well-known shortfall in available human grafts. The world’s first physiological artificial heart that is highly hemocompatible, pulsatile and self-regulated, Aeson® could save, every year, the lives of thousands of patients waiting for a heart transplant. The device offers patients quality of life and mobility thanks to its ergonomic …

89 similar entities Type: Startup Activities: deeptech healthtech manufacturing Technologies: Synthetic Biology

Accelerating drug discovery to transform patients' lives Effective 11/22/21, Acceleron Pharma Inc. is now a wholly-owned subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA (known as MSD outside the United States and Canada) http://merck.com Biopharmaceuticals, Orphan Disease Therapeutics, Rare Diseases, and Serious Diseases

519 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

Bridge-to-recovery by design Systol Dynamics designs and develops an innovative Ventricular Assist Device (VAD) that extends the benefits of mechanical circulatory support to less severe heart failure patients. Uniquely positioned in the aorta by transcatheter implantation, the Systol Dynamics’s VAD is at one minimally-invasive, connected and removable. Unlike terminal solutions, bridge to transplant or destination therapy, it relieves the patient’s heart and enables physiological recovery, ultimately leading to cardiac pump removal. Founded in 2018 by a cardiologist with more than 30 years of experience in the management of cardiac insufficiency, Systol Dynamics is managed by a team of experts in …

59 similar entities Type: Startup Activities: healthtech deeptech Technologies: Synthetic Biology

Transformative vascular implants. Addressing major life-threatening diseases, backed by Nobel-winning science. Xeltis is developing artificial vessels and valves that are gradually replaced by patients’ own living healthy tissue. www.xeltis.com

95 similar entities Type: SMB Activities: healthtech deeptech Technologies: Synthetic Biology

We’re EnovisTM – a global medical technology innovator dedicated to improving lives by developing clinically differentiated solutions that enhance patient outcomes and restore motion for life. We strive to make each day better by partnering with the brightest minds in health to advance care that is smarter, personalized, and more effective, while improving operational efficiency for surgeons and clinicians around the world. We do this through our extraordinary talent, a laser focus on innovation, strategic acquisitions, and a common culture of continuous improvement. With more than 7,000 incredible employees worldwide and an extensive range of products, services, and integrated technologies …

232 similar entities Type: Startup Activities: deeptech healthtech Technologies: Synthetic Biology

Neocor is dedicated to pioneering transformative therapies in cardiac care We are currently developing a novel gene therapy approach targeting ischemic and rare genetic cardiac diseases, and moving from lab preclinical trials to regulatory trials. The Company was founded in October and has received strong traction since inception. We will be looking to strengthen our human and financial ressources in the coming month in order to start the regulatory pre clinical trials. gene therapy, biotechnology, rare disease, and cardiology

337 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Adding Quality Years of Life We are dedicated to improving the lives of patients suffering from hematological malignancies by delivering an innovative immune modulator to enhance the curative potential of allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

113 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Facing the global challenge of the lack of heart grafts, PROCOPE Medicals develops an innovative total artificial heart Thousands of people die every year of severe heart failure, due to the lack of donors, heart transplant is increasingly rare : 3% of patients receive a donor heart. PROCOPE Medicals acts and develops a new generation of artificial heart.

59 similar entities Type: Startup Activities: healthtech deeptech

Heart valves for life, for patients of any age, including children Novostia is a privately held medical device company developing an innovative artificial heart valve, designed for patients of any age, including children. Novostia endeavors to advance its technology to clinical trials and regulatory approvals to improve the quality of life of millions of people worldwide suffering from aortic and mitral valve disease. For more information please visite www.novostia.com Heart Valves and Medical Devices

62 similar entities Type: SMB Activities: healthtech deeptech Technologies: Synthetic Biology

To save more patients from a heart attack ApoRepair is a French biotech company emerging from the National Center for Scientific Research (CNRS) that aims to improve the management of patients in the acute phase of myocardial infarction (MI). Reperfusion of the heart, essential to save the patient's life, generates adverse effects that diminish the expected benefit. Our therapeutic peptide protects the myocardium and improves the effects of reperfusion. This patented technology is based on a collaborative team effort spanning more than 15 years.

75 similar entities Type: Startup Activities: deeptech healthtech Technologies: Synthetic Biology

SignaCor is a clinical stage, drug development company, dedicated to the treatment of cardiac disease. SignaCor is a clinical stage, drug development company, spun-out from Queen’s University Belfast, dedicated to the treatment of cardiac disease. At SignaCor, we are pioneering a first-in-class therapeutic approach to symptomatic hypertrophic cardiomyopathy (HCM)—one that goes beyond symptom management to target the underlying disease pathology. Cardiaza is the first and only treatment that harnesses DNA methylation to address multiple underlying causes of symptomatic HCM, including established fibrosis, a key driver of disease progression.

Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Our purpose is to help millions of people living with heart failure to get their normal back. FIRE1 aims to improve patient quality of life, and patient outcomes, while lowering overall healthcare costs. Health Tech, Research & Development, Medical Devices, Software Engineering, and Clinical

84 similar entities Type: Startup Activities: deeptech Technologies: Synthetic Biology

Unlocking the therapeutic potential of protein stabilisation Outrun Therapeutics is unlocking the therapeutic potential of protein stabilisation by E3 Ligase inhibition for the treatment of cancer and other diseases.

140 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

eMyosound develops an innovative medical device to diagnose heart failure using ultrasound. eMyosound is an innovative med-tech company dedicated to advancing cardiac healthcare through the development of non-invasive ultrasound elastography

62 similar entities Type: Startup Activities: deeptech healthtech Technologies: Synthetic Biology

Ultrasound Guidance during Radio Ablation Treatment of Cardiac Arrhythmias EBAMed (External Beam Ablation Medical) has developed an Ultrasound Imaging Solution to enable non-invasive treatment of Cardiac Arrhythmias. CardioKit is a dedicated cardiorespiratory gating platform developed specifically for cardiac radioablation. It integrates real-time ECG and ultrasound signals with AI-driven cardiac motion tracking to synchronize radiation delivery with the continuously moving cardiac target. When combined with a photon or proton therapy, CardioKit enables precise dose delivery to arrhythmogenic substrates while minimizing exposure to healthy myocardium and surrounding organs.

58 similar entities Type: Startup Activities: healthtech deeptech Technologies: Synthetic Biology

Regain control with personalized muscle regeneration MUVON Therapeutics is a clinical stage Life Science spin-off from the University of Zurich developing a therapeutic platform for the regeneration of skeletal muscle tissue based on autologous cells, not only repairing damaged tissue but also increasing the regenerative potential of weakened muscles. Our initial area of focus is the treatment of stress urinary incontinence in women, supporting them respectfully throughout their journey to a healthy life.

85 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

We believe that everyone - irrespective of who they are or where they live - deserve medications that work We believe that everyone - irrespective of who they are or where they live - deserve medications that work

310 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Empowering Muscle Empowering Lives Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology, and advancing a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction. Heart Failure and Hypertrophic Cardiomyopathy

68 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Innovating Medical Devices Inomed Health Limited is a UK distributor of innovative medical implantable and disposable devices to the NHS and private healthcare institutions. We are a focused company supporting customers and manufacturers to constantly improve the way surgical and non-surgical treatments are performed, delivered through better medical technology to improve the lives of patients. Medical Devices, Interventional Radiology, Biopsy Devices, and Bariatric Health & General Surgery

411 similar entities Type: Startup Activities: deeptech healthtech Technologies: Synthetic Biology

Accessible innovation designed to improve patient outcomes Yorkshire based Med Tech company specialising in Orthopaedics. A small company planning on making a big impact ! Orthopaedics, Medical Devices, and Innovation

314 similar entities Type: Startup Activities: healthtech deeptech Technologies: Synthetic Biology

Ion channel and GPCR drug discovery using innovative KnotBody technology Maxion uses its innovative KnotBody technology in combination with in vitro display technologies to generate therapeutic candidates against ion channels and GPCR proteins.

152 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Delivering longer, better quality lives for brain tumour patients QV Bioelectronics is a VC-backed medical device startup developing an implantable electric field therapy treatment for aggressive brain tumours.

114 similar entities Type: Startup Activities: deeptech healthtech Technologies: Synthetic Biology

Making Regenerative Medicine Accessible Roumai Medical is developing next-generation biotechnologies in regenerative medicine and human-machine interface to meet the unmet clinical needs of millions of patients worldwide.

207 similar entities Type: Startup Activities: healthtech deeptech Technologies: Synthetic Biology

Building on innovative science to create treatments for patients in need ResoTher Pharma ApS is a biotechnology company focused on developing novel and effective peptide therapeutics for cardiovascular disease by targeting inflammation. Biotechnology, Drug Development, and Pharmaceutical Industry

535 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Treating Neurodegenerative Disease by Restoring Autophagy At Samsara Therapeutics, we’re on a mission to unlock the full potential of autophagy activation in combating age-related neurodegenerative diseases. Our innovative approach aims to delay the progression of several debilitating conditions, offering new possibilities for patients and their families. biotechnology, biopharmaceuticals, rare disease, neurodegeneration, longevity, drug discovery, and drug development

428 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

The objective of Quantum Genomics is to become a leading actor in the treatment of cardio-vascular diseases through the development of a new therapeutic class: BAPAIs for BrainAminopeptidase A Inhibitors. We wish to develop and provide effective and well tolerated therapeutic treatments for controlling high blood pressure and to for preventing related cardio-vascular risks such as heart failure. High blood pressure remains a major public health concern. Quantum Genomics is the only biopharmaceutical research company developing new therapies from a real breakthrough innovation based on the inhibition of brain Aminopeptidase A. The mid-term strategic objective of the company is to …

62 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Redefining Cardiac Ablation, Coherent Sine-burst electroporation (CSE), innovation, pulsed field ablation (PFA) Argá Medtech SA is a privately-held medical device company based in Switzerland founded by seasoned team of leaders in the industry. Argá is developing an innovative non-thermal energy based cardiac ablation system for the treatment of cardiac arrhythmias. With the use of Pulsed Electrical Fields (PEF) to create irreversible electroporation (IRE) of cardiomyocytes, Argá is developing a safer, faster, cheaper and more effective cardiac ablation treatment for the benefit of millions of people affected by cardiac rhythm disorders and atrial fibrillation. cardiology, cardiac ablation, PFA, IRE, PEF, electro …

56 similar entities Type: Startup Activities: deeptech manufacturing Technologies: Synthetic Biology

Committed to saving lives. Hemarina is an innovative biotechnology company specializing in health product development based in Morlaix (29600, FR). Our search for new solutions based on the properties of the haemoglobin of the arenicola marina worm is permanent to improve the quality of life of patients and their families. Our commitment: to save lives by putting the patient at the heart of all our actions. BioTech, Ocean, Biomimicry, Biology, Biodiversity, and Transplantation

77 similar entities Type: SMB Activities: deeptech Technologies: Synthetic Biology

Decoding cardiovascular disease biology for novel therapeutic discovery CardiaTec harnesses human heart multiomics data and computational modelling to develop first-in-class cardiovascular therapies. Powered by a global network of 65 hospitals, the company is developing the largest proprietary human cardiac multiomics dataset, enriched with clinical annotations to unlock novel insights into disease biology. With experts from leading organisations such as Bristol Myers Squibb, AbbVie, and Recursion, CardiaTec is redefining the discovery and development of precision cardiovascular therapies.

71 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

We are a biopharmaceutical company dedicated to transforming the future for underserved, global patient populations in bone health and related areas. We consistently embrace opportunities to improve the lives of our patients, their caregivers, our communities, our partners, and each other.

284 similar entities Type: SMB Activities: healthtech deeptech Technologies: Synthetic Biology

Shaping the future of regenerative medicine At 4Tissue, we’re pioneering the future of regenerative medicine with innovative hydrogel solutions that support natural tissue restoration. We are an innovation-led research and clinical development organization. Our mission is to redefine the boundaries of tissue reconstruction, regeneration, and anti-aging, utilizing innovative biocompatible and bioresorbable polymers platform The first product, a bioresorbable injectable hydrogel, is focused on a better cell survival and the full regeneration of adipose tissue for breast reconstruction and augmentation applications.

118 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology SaaS

Develop human organ models with true physiological complexity We are specialized in the production and development of human, immunocompetent Organ-on-Chip technology for in vitro disease and infection modelling. Organ-on-Chip, Human Cell Biology, Infection, Infectious disease, Toxicity profiling, Immune Cell Interactions, Inflammatory Diseases, Antibody recycling, and Uptake / Transport studies

263 similar entities Type: Startup Activities: manufacturing biotech deeptech Technologies: Synthetic Biology

Driven by innovation to contribute to a healthier and happier life We share a deep commitment to service and customer service, which, combined with our professionalism, helps us achieve our primary objective: giving a longer, healthier, happier life to society by offering safe and efficacious drugs. We are able to achieve this goal through research and analysis, as well as an understanding of the needs of our patients, professionals, distributors and institutional representatives. Medicamentos de prescripción, Nutraceuticos, and Productos farmacéuticos

297 similar entities Type: SMB Activities: deeptech Technologies: Synthetic Biology

CardioScale is an Israeli medical device start-up founded 2012, pursuing a novel patent applied diagnostic for early detection of cardiovascular deterioration in various patients of heart failure and shock.

139 similar entities Type: Startup Activities: healthtech deeptech Technologies: Synthetic Biology

Transforming Energy into Therapy Galvanize Therapeutics is developing therapies to deliver life-changing healthcare solutions to patients and their doctors at the convergence of biology, engineering, and care delivery. medical device, COPD, AF, Oncology, Intervential Oncology, Intervential Pulmonology, AFib, PEF, PEF Ablation, Soft Tissue Ablation, Cardiac Arrhythmias, and Chronic Bronchitis

451 similar entities Type: Startup Activities: deeptech healthtech Technologies: Synthetic Biology

Technologies for your heart J.E.M. Tech has developed and created the first Videocardiograph (VCG): a non-invasive medical device based on artificial intelligence (A.I.) capable of evaluating the mechanical function of the heart in real time only via a camera. The VCG can be consulted by cardiac surgeons, whenever they feel the need during the operation, to evaluate cardiac behavior. The vision of J.E.M. Tech is to provide a non-invasive personalized medicine medical device capable of preventing mortality in cardiac patients, improving diagnosis, prognosis and reducing the time spent in intensive care after surgery. The mission of J.E.M. Tech is to …

65 similar entities Type: Startup Activities: healthtech deeptech Technologies: Synthetic Biology

Activating RNA, mastering disease Harnessing an innate mechanism of gene activation, MiNA Therapeutics'​ platform enables the development of new medicines that restore normal function to patients’ cells. We are applying our technology and clinical know-how to transform the therapy landscape of severe liver and other diseases. Gene activation, RNA therapeutics, Liver disease, and Drug discovery

228 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Developing novel medications for patients with atrial fibrillation InCarda Therapeutics is a privately held biotechnology company backed by leading VC investors, Deerfield Management and HealthCap, developing novel drugs for the treatment of patients with atrial fibrillation (“AF”). Our mission is to enable rapid restoration of normal sinus rhythm ("NSR") with therapies designed to be fast-acting, safe, simple to use, and available across the continuum of care—from hospital-based cardioversion to at-home, self-administered treatment. Cardiovascular, Biotechnology, Pharmaceuticals, Clinical Development, Drug Formulation, Clinical Research, Pre-Clinical Research, atrial fibrillation, and arrhythmias

127 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Delivering Hope to the Heart of our Patients AuriGen Medical are an EUeic supported medical device start up, developing the next generation in left atrial appendage implant technology for the treatment of medication resistant longstanding persistent atrial fibrillation. #EUeic #eicAccelerator

93 similar entities Type: Startup Activities: deeptech healthtech Technologies: Synthetic Biology

The Cell Therapy Venture Builder MedXCell is a European cell therapy venture builder with a strong industrial mindset and a global perspective. Our focus is on technologies, techniques or novel applications in major diseases such as cancer, autoimmune, neurological and degenerative disorders. Established in 2018, we have offices in Switzerland, the EU (France) and the US (Cambridge, MA) and a multidisciplinary expert team with entrepreneurial, clinical, operational, business development and funding capabilities. Biotechnology, Cell Therapy, Immunotherapy, NK Cells, Mesenchymal Stromal Cells, Immuno-oncology, and Osteoarthritis

582 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Technology-driven biotech with an AI-powered miniprotein RnD platform VRG Tx is technology-driven biotech with a drug discovery platform that integrates AI with wet lab processes to develop next-generation therapeutics. Our vision is to cure diseases through previously undruggable targets and inaccessible mechanisms of action. medicinal biotechnology, research, immunology autoimmune deases , translational health research, use of genetic engineering in medicine, anti cancer drug discovery, oncological drugs, autoimmune diseases, translational research, peptide, cellandgenetherapy, and genetherapy

589 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Interventions for Human Diseases Venture-funded company, discovering and developing oral novel small molecule first-in-class inhibitors of Bach1 (a transcription factor) as transformative potential therapy, globally accessible for patients with sickle cell disease (SCD), renal, cardiometabolic and neurodegenerative and other diseases. Sickle Cell Disease, fetal hemoglobin induction, beta-thalassemia, Renal diseases, cardiometabolic diseases, and neurodegenerative diseases

184 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Cardiac Microcurrent C-MIC - A novel therapy for chronic heart failure Berlin Heals is a Start-up-Company in Berlin, Germany. We are devoted to the treatment of heart failure. We will redefine heart failure treatment with a novel device that is capable of healing the heart. Contact us at info@berlinheals.de to get in touch with us. Get more Information here: www.berlinheals.de R+D and Marketing of a novel cardiovascular device

67 similar entities Type: Startup Activities: deeptech healthtech biotech

Securing your vision Recornea is a clinical stage medtech ophthalmic company developing therapeutic solutions for treating diseases of the cornea, such as keratoconus, glaucoma and corneal transplants.

110 similar entities Type: Startup Activities: healthtech deeptech Technologies: Synthetic Biology

Surgical tissue repair At Regenosca, we’re pioneering the future of regenerative medicine with a breakthrough platform that enables the body to heal itself—without synthetic implants or tissue grafts. Our 100% engineered, natural collagen scaffolds guide perfect tissue regeneration, offering a safer and more effective alternative to traditional treatments. With 100% success in urethra reconstruction—our initial indication in urology—demonstrated in a first-in-human trial (sustained at two-year follow-up), we’re proving the potential of our technology to transform tissue restoration across multiple medical fields. Our goal? To make tissue regeneration a reality for patients worldwide, through collaborations with clinicians, researchers, and industry partners. …

70 similar entities Type: Startup Activities: deeptech Technologies: Synthetic Biology

Build a Heart. Save a Life. Pioneered by accomplished business leaders, guided by world-class biomedical and life science experts, and financed through equity crowdfunding, BIOLIFE4D is driving a movement to transform the treatment of heart disease, the leading cause of death worldwide. Leveraging advances in life sciences and cardiac tissue engineering to build human hearts suitable for implantation, this biotech company is committed to optimizing the process and technology around viable human organ replacement, and making it a safe, accessible, commercially viable, and cost-effective reality.

63 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Allogeneic Cell Therapy Platform that Leverages Natural Platelet Biology PlateletBio is an allogeneic cell therapy company focused on platelet biology. We are pioneers, discovering a new category in therapeutics. Our approach is one-of-a-kind, recreating nature’s legendary delivery cell. In doing so, we’re developing a cell therapy empowered to tackle previously unmet medical challenges. biotechnology, platelets, and drug discovery

459 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Engineering Stroke Solutions ENGINEERING Stroke Solutions Acandis, founded in 2006, is a privately held German medical device company focused on the prevention and treatment of stroke. We have a passion for technology and our engineers are enthusiastic about creating solutions for unmet clinical needs to improve patient’s lives. We strive towards a comprehensive device portfolio and continuous development of products and services to improve stroke care for neurointerventionalists around the globe. The safety of our products has been demonstrated on the bench top and now the efficacy of those products is being proven in clinical trials. As a company we …

296 similar entities Type: SMB Activities: deeptech healthtech biotech Technologies: Synthetic Biology

Agomab is translating a deep expertise in growth factor biology to pioneer and develop novel treatments that aim to resolve fibrosis, repair tissue structure and restore organ function. Combining new scientific insights with robust drug development and a long-term corporate vision, we are building a broad clinical pipeline of differentiated programs with disease modifying potential in severe organ failure and fibrotic diseases.

172 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

a leader in the development of comprehensive solutions for cardiovascular regenerative therapies We are a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases with large unmet medical needs. BioCardia is developing proprietary comprehensive biotherapeutic solutions for cardiovascular disease in its CardiAMPTM and CardiALLOTM therapies. Clinical results supporting both therapeutic programs are compelling and build upon the most rigorous data in the field to date with intramyocardial delivery of marrow-derived cells. These programs are enabled by the Company's HelixTM transendocardial delivery systems and Morph® vascular access products, which are partnered to enable other promising biotherapeutic programs.

72 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

First and Only FDA Approved Restorative Therapy for Chronic Mechanical Low Back Pain Mainstay Medical, led by a team of dedicated scientists, executives, engineers, and clinical experts, brings to you ReActiv8®, the first and only FDA-approved restorative treatment for mechanical chronic low back pain. RESTORE Control RESTORE Function RESTORE Stability ReActiv8 LIFE The Company was incorporated in Dublin, Ireland and headquartered in San Diego, CA. It has subsidiaries operating in Ireland, the United States, Australia, Germany and the Netherlands.

66 similar entities Type: SMB Activities: deeptech healthtech Technologies: Synthetic Biology

Anteris® Technologies is a global structural heart company dedicated to revolutionizing cardiac care. Anteris® Technologies is a global structural heart company dedicated to revolutionizing cardiac care. Our mission is to forge new frontiers in cardiac care by pioneering science-driven and measurable advancements to restore heart valve patients to healthy function. Transcatheter Aortic Valve Replacement (TAVR) technologies were originally designed for older, high-risk patients. Today, younger, more active patients need a better solution that will not just open and close but restore healthy heart function. We sought to restore healthy blood flow patterns by creating the world’s first biomimetic TAVR valve, …

61 similar entities Type: SMB Activities: healthtech deeptech

Developing next-generation lipid nanoparticle delivery systems to unlock the potential of RNA therapeutics Axelyf was founded in Iceland in 2022 with the goal of harnessing health benefits of natural molecules through chemistry and delivery engineering.

169 similar entities Type: Startup Activities: healthtech deeptech Technologies: Synthetic Biology